B Cells are lymphocytes responsible for central components of humoral adaptive immunity. They develop from haematopoietic precursors primarily in the bone marrow and acquire antigen-specific B-cell receptors during maturation. Mature B cells can recognise antigen through their surface immunoglobulin and, after appropriate activation, can differentiate into plasma cells that secrete antibodies or memory B cells that persist after the initial immune response. B cells also have antigen-presenting and regulatory functions. Their name historically derives from the bursa of Fabricius in birds, where analogous cells were first identified as important for antibody production; in mammals, B-cell development occurs primarily in bone marrow.
The B-cell receptor is a membrane-bound immunoglobulin associated with signalling proteins that transmit activation signals into the cell. B-cell receptor diversity is generated through V(D)J recombination during development, producing large numbers of B-cell clones with different antigen specificities. Unlike T-cell receptors, B-cell receptors can bind intact antigen directly without requiring the antigen to be presented by MHC. This allows B cells to recognise particular molecular shapes, including conformational epitopes on proteins. Successful B-cell development also involves mechanisms that reduce strong self-reactivity, contributing to central and peripheral tolerance.
B-cell activation can occur through different pathways. Many protein antigens produce T-dependent responses in which B cells internalise antigen, process it and present peptide fragments to helper T cells, particularly T follicular helper cells. Signals through CD40 and cytokines then support proliferation, differentiation and germinal-centre reactions. Some non-protein antigens can stimulate T-independent responses, often producing relatively rapid antibody production with less extensive affinity maturation and memory. The distinction between these pathways is important because it explains why different antigen types can generate different qualities of antibody response.
Plasma cells are specialised antibody-secreting descendants of activated B cells. Some plasma cells are short-lived and contribute to early antibody production, while long-lived plasma cells can reside in specialised niches and continue producing antibodies for extended periods. Memory B cells persist after an immune response and can respond rapidly to subsequent exposure. These two outcomes serve different purposes: plasma cells provide ongoing antibody production, whereas memory B cells provide a reservoir of antigen-specific cells capable of generating renewed responses. Together they form important components of long-term humoral immunity.
Germinal centres are specialised structures within secondary lymphoid tissues where activated B cells undergo proliferation, somatic hypermutation and selection for improved antigen-binding affinity. Class-switch recombination allows B cells to change the antibody isotype they produce while retaining antigen specificity. These processes depend heavily on interactions with T follicular helper cells and specialised stromal and antigen-presenting environments. The result can be a population of B cells capable of producing antibodies with improved affinity and effector properties appropriate to the anatomical site and type of immune response.
B cells also contribute to immunity by presenting antigen to T cells. After binding antigen through their B-cell receptors, B cells can internalise the material, process protein components and present peptides on MHC class II. This makes them particularly efficient at presenting antigen to T cells when the antigen is specifically recognised by the B-cell receptor. B cells can additionally secrete cytokines and participate in immune regulation. Consequently, defining B Cells solely as antibody-producing cells omits important roles they play in antigen presentation, immune communication and regulation.
B-cell abnormalities can cause both insufficient and excessive immune activity. Defective B-cell development or function can reduce antibody-mediated defence and increase susceptibility to particular infections. Conversely, abnormal B-cell activation can contribute to autoimmune disease, in which antibodies or other B-cell functions target self structures. Malignant transformation can produce B-cell cancers such as various lymphomas and leukaemias. Therapeutic antibodies targeting B-cell-associated molecules can therefore be used to deplete particular B-cell populations or modify their activity in selected diseases.
B Cells are central to vaccination because many vaccines aim to establish durable antibody and memory B-cell responses against defined antigens. Effective B-cell responses require an appropriate combination of antigen recognition, cellular interactions, cytokine signalling and tissue context. Antibody titres can provide useful evidence of humoral response but do not always perfectly predict protection because protective immunity can also involve T cells and other mechanisms. B-cell memory likewise varies according to the antigen and vaccine. Understanding B Cells therefore requires considering development, receptor diversity, activation pathways, germinal centres, plasma cells, memory, antigen presentation and tolerance.
